Share Price and Basic Stock Data
Last Updated: October 22, 2025, 5:07 am
| PEG Ratio | 1.26 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Syncom Formulations (India) Ltd operates in the pharmaceuticals sector, showcasing a steady growth trajectory in revenue over recent years. For the fiscal year ending March 2025, the company reported sales of ₹463 Cr, a significant increase from ₹222 Cr in March 2023. Quarterly sales figures reveal a consistent upward trend, with the most recent quarter (September 2023) recording sales of ₹62 Cr. The company’s operating profit margin (OPM) stood at 12% for March 2025, which is an improvement from 9% in March 2023. This positive trend in revenue is bolstered by an efficient cost management strategy, as expenses rose at a slower pace than sales, indicating effective operational control. The cash conversion cycle (CCC) for the latest fiscal year was reported at 83 days, suggesting that the company is effectively managing its working capital despite the increase in sales. Overall, Syncom Formulations demonstrates robust revenue growth, positioning itself well within the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Profitability metrics for Syncom Formulations reveal a solid performance, with net profit rising to ₹49 Cr in March 2025, up from ₹20 Cr in March 2023. The net profit margin improved to 10.63% compared to 9% in the previous year, reflecting enhanced operational efficiency. The return on equity (ROE) stood at 14.44% for March 2025, which is notably higher than the industry average, indicating effective use of shareholders’ funds. The interest coverage ratio (ICR) was an impressive 82.74x, demonstrating the company’s ability to meet its interest obligations comfortably. However, while the return on capital employed (ROCE) improved to 18.75%, it still suggests potential room for enhancement compared to sector benchmarks. The company’s operational performance, underscored by increasing profitability and efficient capital utilization, positions it favorably among peers in the pharmaceuticals sector.
Balance Sheet Strength and Financial Ratios
Syncom Formulations maintains a robust balance sheet, characterized by minimal debt levels. As of March 2025, total borrowings were merely ₹4 Cr, resulting in a debt-to-equity ratio of 0.01, indicating a conservative capital structure. The reserves have increased significantly to ₹246 Cr from ₹162 Cr in March 2023, showcasing the company’s ability to accumulate retained earnings effectively. The current ratio was reported at 4.55, reflecting excellent liquidity and the ability to cover short-term liabilities comfortably. Furthermore, the price-to-book value (P/BV) ratio stood at 4.52x, suggesting that the stock is trading at a premium relative to its book value, which may indicate investor confidence in future growth prospects. These financial ratios highlight Syncom Formulations’ strong financial position, supported by low leverage and high liquidity, which are critical for navigating potential market challenges.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syncom Formulations indicates a stable structure, with promoters holding 50.57% of the company’s equity, reflecting a strong commitment to the business. The public shareholding stands at 49.02%, while Foreign Institutional Investors (FIIs) have gradually increased their stake to 0.41% as of March 2025, up from negligible levels in previous quarters. This gradual increase in FII participation may signal growing investor confidence in the company’s growth trajectory. However, the absence of Domestic Institutional Investors (DIIs) may suggest a lack of interest from larger domestic funds, which could be a potential risk. The total number of shareholders has also seen fluctuations, with a reported 471,066 shareholders as of June 2025, indicating a broad base of retail investors. Overall, the shareholding pattern reflects both stability and emerging interest from foreign investors, which could positively influence the stock’s liquidity and valuation.
Outlook, Risks, and Final Insight
If margins sustain their upward trajectory alongside revenue growth, Syncom Formulations could enhance its competitive positioning within the pharmaceuticals sector. The company’s low debt levels and high liquidity present a solid foundation for further investments and expansion initiatives. Potential risks include fluctuations in raw material costs and regulatory challenges inherent to the pharmaceutical industry, which could impact profitability. Additionally, the lack of significant institutional backing may pose challenges in terms of stock liquidity and market perception. Nevertheless, if the company continues to manage its costs effectively and maintain its operational efficiency, it is well-positioned to capitalize on growth opportunities in the pharmaceutical market, particularly with its expanding product portfolio and increasing sales momentum.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Syncom Formulations (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 54 | 57 | 61 | 59 | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 |
| Expenses | 48 | 50 | 51 | 55 | 53 | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 |
| Operating Profit | 3 | 4 | 6 | 6 | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 |
| OPM % | 7% | 8% | 10% | 10% | 10% | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% |
| Other Income | 3 | 3 | 2 | 7 | 2 | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 6 | 10 | 6 | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 |
| Tax % | 22% | 33% | 30% | 18% | 27% | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% |
| Net Profit | 4 | 4 | 4 | 8 | 4 | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 |
| EPS in Rs | 0.04 | 0.04 | 0.04 | 0.09 | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 |
Last Updated: August 20, 2025, 2:45 am
Below is a detailed analysis of the quarterly data for Syncom Formulations (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 117.00 Cr.. The value appears to be declining and may need further review. It has decreased from 148.00 Cr. (Mar 2025) to 117.00 Cr., marking a decrease of 31.00 Cr..
- For Expenses, as of Jun 2025, the value is 101.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 131.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 30.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Mar 2025) to 14.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Mar 2025) to 22.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.17. The value appears to be declining and may need further review. It has decreased from 0.19 (Mar 2025) to 0.17, marking a decrease of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:20 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 257 | 461 | 494 |
| Expenses | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 229 | 407 | 434 |
| Operating Profit | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 54 | 60 |
| OPM % | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 12% | 12% |
| Other Income | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 17 | 21 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 65 | 75 |
| Tax % | 33% | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | 24% | |
| Net Profit | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 49 | 57 |
| EPS in Rs | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.52 | 0.62 |
| Dividend Payout % | 17% | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 13% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.11% | 0.00% | 10.00% | -18.18% | 22.22% | 27.27% | 107.14% | -31.03% | 0.00% | 20.00% | 104.17% |
| Change in YoY Net Profit Growth (%) | 0.00% | -11.11% | 10.00% | -28.18% | 40.40% | 5.05% | 79.87% | -138.18% | 31.03% | 20.00% | 84.17% |
Syncom Formulations (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 18% |
| 3 Years: | 29% |
| TTM: | 73% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 35% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 59% |
| 3 Years: | 26% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: September 10, 2025, 2:36 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 | 94 |
| Reserves | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 109 | 136 | 162 | 192 | 246 |
| Borrowings | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | 4 |
| Other Liabilities | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 42 | 28 | 38 | 33 | 66 |
| Total Liabilities | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 |
| Fixed Assets | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | 125 |
| CWIP | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 | 0 |
| Investments | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 | 93 |
| Other Assets | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | 192 |
| Total Assets | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 |
Below is a detailed analysis of the balance sheet data for Syncom Formulations (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 94.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 94.00 Cr..
- For Reserves, as of Mar 2025, the value is 246.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 246.00 Cr., marking an increase of 54.00 Cr..
- For Borrowings, as of Mar 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 72.00 Cr. (Mar 2024) to 4.00 Cr., marking a decrease of 68.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 66.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2024) to 66.00 Cr., marking an increase of 33.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 410.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 392.00 Cr. (Mar 2024) to 410.00 Cr., marking an increase of 18.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 120.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 93.00 Cr.. The value appears strong and on an upward trend. It has increased from 66.00 Cr. (Mar 2024) to 93.00 Cr., marking an increase of 27.00 Cr..
- For Other Assets, as of Mar 2025, the value is 192.00 Cr.. The value appears to be declining and may need further review. It has decreased from 206.00 Cr. (Mar 2024) to 192.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Mar 2025, the value is 410.00 Cr.. The value appears strong and on an upward trend. It has increased from 392.00 Cr. (Mar 2024) to 410.00 Cr., marking an increase of 18.00 Cr..
Notably, the Reserves (246.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 13.00 | 12.00 | 11.00 | 4.00 | 0.00 | 3.00 | 15.00 | -24.00 | -38.00 | -63.00 | -44.00 | 50.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 | 85 |
| Inventory Days | 36 | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 | 49 |
| Days Payable | 105 | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 | 51 |
| Cash Conversion Cycle | 1 | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 | 83 |
| Working Capital Days | 75 | 84 | 40 | 45 | 75 | 74 | 88 | 28 | 33 | -4 | 51 | 95 |
| ROCE % | 15% | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 5,387 | 0.09 | 0.01 | 5,387 | 2025-04-22 16:59:38 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 17 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.26 | 0.13 |
| Diluted EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.24 | 0.13 |
| Cash EPS (Rs.) | 0.58 | 0.31 | 0.26 | 0.27 | 0.17 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Revenue From Operations / Share (Rs.) | 4.95 | 2.80 | 2.39 | 2.55 | 2.37 |
| PBDIT / Share (Rs.) | 0.76 | 0.45 | 0.36 | 0.37 | 0.24 |
| PBIT / Share (Rs.) | 0.70 | 0.40 | 0.31 | 0.32 | 0.20 |
| PBT / Share (Rs.) | 0.69 | 0.36 | 0.28 | 0.30 | 0.20 |
| Net Profit / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| NP After MI And SOA / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| PBDIT Margin (%) | 15.39 | 16.39 | 15.26 | 14.58 | 10.43 |
| PBIT Margin (%) | 14.27 | 14.59 | 13.23 | 12.78 | 8.74 |
| PBT Margin (%) | 14.08 | 12.89 | 11.84 | 11.91 | 8.59 |
| Net Profit Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| NP After MI And SOA Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| Return on Networth / Equity (%) | 14.44 | 8.78 | 7.83 | 8.90 | 8.97 |
| Return on Capital Employeed (%) | 18.75 | 12.89 | 11.21 | 12.20 | 12.92 |
| Return On Assets (%) | 11.96 | 6.25 | 5.31 | 6.42 | 5.84 |
| Total Debt / Equity (X) | 0.01 | 0.25 | 0.32 | 0.26 | 0.10 |
| Asset Turnover Ratio (%) | 1.14 | 0.67 | 0.65 | 0.00 | 1.05 |
| Current Ratio (X) | 4.55 | 2.58 | 1.61 | 1.79 | 1.50 |
| Quick Ratio (X) | 3.85 | 2.38 | 1.42 | 1.54 | 1.32 |
| Inventory Turnover Ratio (X) | 8.91 | 6.22 | 4.89 | 0.00 | 5.42 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 14.82 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 11.43 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.18 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 88.57 |
| Interest Coverage Ratio (X) | 82.74 | 9.65 | 10.93 | 16.62 | 68.46 |
| Interest Coverage Ratio (Post Tax) (X) | 58.15 | 6.66 | 7.41 | 11.25 | 38.42 |
| Enterprise Value (Cr.) | 1550.17 | 1055.54 | 629.15 | 974.19 | 159.72 |
| EV / Net Operating Revenue (X) | 3.33 | 4.01 | 2.81 | 4.43 | 0.86 |
| EV / EBITDA (X) | 21.66 | 24.45 | 18.38 | 30.42 | 8.28 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.17 |
| Price / BV (X) | 4.52 | 3.65 | 2.17 | 4.13 | 1.31 |
| Price / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.06 |
After reviewing the key financial ratios for Syncom Formulations (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 3. It has increased from 0.31 (Mar 24) to 0.58, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.95. It has increased from 2.80 (Mar 24) to 4.95, marking an increase of 2.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 2. It has increased from 0.45 (Mar 24) to 0.76, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.70. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.70, marking an increase of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.36 (Mar 24) to 0.69, marking an increase of 0.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For PBDIT Margin (%), as of Mar 25, the value is 15.39. This value is within the healthy range. It has decreased from 16.39 (Mar 24) to 15.39, marking a decrease of 1.00.
- For PBIT Margin (%), as of Mar 25, the value is 14.27. This value is within the healthy range. It has decreased from 14.59 (Mar 24) to 14.27, marking a decrease of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 14.08. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 14.08, marking an increase of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 10.63. This value exceeds the healthy maximum of 10. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 15. It has increased from 8.78 (Mar 24) to 14.44, marking an increase of 5.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.75. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 18.75, marking an increase of 5.86.
- For Return On Assets (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from 6.25 (Mar 24) to 11.96, marking an increase of 5.71.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.01, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has increased from 0.67 (Mar 24) to 1.14, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 2.58 (Mar 24) to 4.55, marking an increase of 1.97.
- For Quick Ratio (X), as of Mar 25, the value is 3.85. This value exceeds the healthy maximum of 2. It has increased from 2.38 (Mar 24) to 3.85, marking an increase of 1.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.91. This value exceeds the healthy maximum of 8. It has increased from 6.22 (Mar 24) to 8.91, marking an increase of 2.69.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 82.74. This value is within the healthy range. It has increased from 9.65 (Mar 24) to 82.74, marking an increase of 73.09.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 58.15. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 58.15, marking an increase of 51.49.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,550.17. It has increased from 1,055.54 (Mar 24) to 1,550.17, marking an increase of 494.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.33, marking a decrease of 0.68.
- For EV / EBITDA (X), as of Mar 25, the value is 21.66. This value exceeds the healthy maximum of 15. It has decreased from 24.45 (Mar 24) to 21.66, marking a decrease of 2.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 4.52. This value exceeds the healthy maximum of 3. It has increased from 3.65 (Mar 24) to 4.52, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syncom Formulations (India) Ltd:
- Net Profit Margin: 10.63%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.75% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.44% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 58.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.7 (Industry average Stock P/E: 50.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.63%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 7, Niraj Industrial Estate, Mumbai Maharashtra 400093 | finance@sfil.in http://www.sfil.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kedarmal Shankarlal Bankda | Exe.Chairman & W T D |
| Mr. Vijay Shankarlal Bankda | Managing Director |
| Mrs. Rinki Ankit Bankda | Whole Time Director |
| Mrs. Ruchi Jindal | Independent Woman Director |
| Mr. Ritesh Kumar Lunkad | Independent Director |
| Mr. Ankit Jain | Independent Director |
FAQ
What is the intrinsic value of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's intrinsic value (as of 25 October 2025) is 12.68 which is 24.52% lower the current market price of 16.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,576 Cr. market cap, FY2025-2026 high/low of 24.0/14.1, reserves of ₹246 Cr, and liabilities of 410 Cr.
What is the Market Cap of Syncom Formulations (India) Ltd?
The Market Cap of Syncom Formulations (India) Ltd is 1,576 Cr..
What is the current Stock Price of Syncom Formulations (India) Ltd as on 25 October 2025?
The current stock price of Syncom Formulations (India) Ltd as on 25 October 2025 is 16.8.
What is the High / Low of Syncom Formulations (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syncom Formulations (India) Ltd stocks is 24.0/14.1.
What is the Stock P/E of Syncom Formulations (India) Ltd?
The Stock P/E of Syncom Formulations (India) Ltd is 27.7.
What is the Book Value of Syncom Formulations (India) Ltd?
The Book Value of Syncom Formulations (India) Ltd is 3.62.
What is the Dividend Yield of Syncom Formulations (India) Ltd?
The Dividend Yield of Syncom Formulations (India) Ltd is 0.00 %.
What is the ROCE of Syncom Formulations (India) Ltd?
The ROCE of Syncom Formulations (India) Ltd is 18.6 %.
What is the ROE of Syncom Formulations (India) Ltd?
The ROE of Syncom Formulations (India) Ltd is 15.5 %.
What is the Face Value of Syncom Formulations (India) Ltd?
The Face Value of Syncom Formulations (India) Ltd is 1.00.